Video
Dr. Dorff on greatest unmet need in metastatic castration-sensitive prostate cancer
Author(s):
Tanya Dorff, MD, explains how the next frontier in mCSPC will be the ability to select patients for treatment based more on molecular stratification and not only on disease volume or metachronous vs synchronous presentation.
Video Player is loading.
Tanya Dorff, MD, describes biomarkers as the critical component to advancing the treatment paradigm for patients with metastatic castration-sensitive prostate cancer. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.
Related Videos
Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
Paul Sieber, MD, on the future of genetic testing in prostate cancer
Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer
Tim Richardson, MD, on genetic testing in the era of targeted therapies
Discussing germline testing for prostate cancer with veterans
Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
Germline testing study’s implications for veteran access to prostate cancer treatments
Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
Daniel Kwon, MD, on germline testing for prostate cancer in veterans with service-connected benefits
Related Content
